Scientific advisors & partners update

IXICO plc

08 June 2026

 

IXICO plc

("IXICO", the "Company" or the "Group")

IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER'S AND PARKINSON'S DISEASE

Professor Jeffrey Cummings and Professor Charles DeCarli in the field of Alzheimer's Disease, and Professor Stéphane Lehéricy in the field of Parkinson's Disease join the IXICO Scientific Advisory Board

Parkinson's disease research activities include collaboration with the Paris Brain Institute and advisory role with The Michael J. Fox Foundation for Parkinson's Research

08 June 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has added three further global experts with Professor Cummings and Professor DeCarli, leading KOLs in Alzheimer's Disease (AD) and, Professor Lehéricy a leading KOL in  Parkinson's Disease (PD), to its Scientific Advisory Board. IXICO also announced today that it has entered into two scientific R&D initiatives in the field of PD.  

Scientific Advisory Board Additions

Professor Jeffrey Cummings, MD, ScD, University of Nevada Las Vegas

Jeff is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). A full biography is available in the notes at the bottom of this announcement.

Professor Charles DeCarli, MD, University of California

Charles is Distinguished Professor of Neurology at the University of California in Davis, California and recipient of the Victor and Genevieve Orsi Chair in Alzheimer's Research. He is Co-Director of the UC Davis Alzheimer's Disease Research Center (UCD ADRC), and Chief of the Imaging of Dementia and Aging (IDeA) laboratory.  A full biography is available in the notes at the bottom of this announcement.

Professor Stéphane Lehéricy, MD,  Paris Brain Institute

Stéphane Lehéricy is Professor of Neuroradiology and head of the neuroradiology department at the Pitié-Salpêtrière Hospital (Paris) and Director of CENIR (Centre de neuro-imagerie de recherche) at the Paris Brain Institute. His area of research is the structural and functional study of the normal and pathological human brain, including movement pathology and neurodegenerative dementia.  A full biography is available in the notes at the bottom of this announcement.

Scientific Collaborations

Paris Brain Institute

IXICO has entered into a research collaboration with the Paris Brain Institute (ICM) to conduct a prospective  study evaluating a number of new neuromelanin-sensitive MRI approaches as a potential imaging biomarker approach for use in clinical research in PD. The study will focus on optimising MRI acquisition protocols and applying advanced AI-driven analysis to improve the robustness and reproducibility of this emerging imaging technique, supporting its adoption as a quantitative imaging biomarker in PD clinical trials.

The Michael J. Fox Foundation for Parkinson's Research (MJFF) - MRI Advisory Committee

Robin Wolz, CSO/CMO at IXICO and Kirsi Kinnunen, Principal Biomarker Scientist at IXICO have been invited to participate in  MJFF's MRI Advisory Committee, which brings together researchers and experts working in neuroimaging and biomarker research related to Parkinson's disease. The committee is part of a broader precompetitive public-private effort that convenes academic leaders, industry partners, and nonprofit stakeholders to advance the development, standardisation, and validation of quantitative MRI biomarkers for PD research. Through collaboration on protocols, data sharing, and reproducibility, the committee supports the evaluation of imaging biomarkers that could ultimately improve the measurement of disease progression and therapeutic response in clinical trials.

Robin Wolz, Chief Scientific and Medical Officer of IXICO, commented:  "IXICO's business proposition is grounded in science, which is why working with some of the world's most important KOLs ensures the validation and clinical relevance of the services and technology we provide to the biopharma industry. In addition, adding further expertise and collaborative R&D activity, including our research collaboration with the Paris Brain Institute and participation in MRI biomarker advisory activities, IXICO further deepens its presence in the CNS space.  

I'm delighted to welcome Jeff, Charlie and Stéphane to the Scientific Advisory Board adding knowledge and experience to an already strong group of advisors.  We will continue to explore opportunities to work with the most important individuals and organisations pioneering progress towards better understanding, diagnosis, and treatment of neurodegenerative disease."

Ends

For further information please contact:

IXICO plc	[phone]
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)	[phone]
Giles Balleny, Isaac Hooper (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

Professor Jeffrey Cummings, MD, ScD, University of Nevada Las Vegas

Jeff is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr Cummings is globally recognized for his contributions to Alzheimer's research, drug development, and clinical trials. Dr Cummings interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. He has authored or edited 43 books and published over 800 peer-reviewed papers.

Dr Cummings was formerly Augustas Rose Professor of Neurology and Professor of Psychiatry at UCLA, Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. He is past president of the Behavioural Neurology Society and of the American Neuropsychiatric Association. 

Professor Charles DeCarli, MD, University of California

Charles is Distinguished Professor of Neurology at the University of California in Davis, California and recipient of the Victor and Genevieve Orsi Chair in Alzheimer's Research. He is Co-Director of the UC Davis Alzheimer's Disease Research Center (UCD ADRC), a United States National Institutes of Health funded Alzheimer's research centre. He is also Chief of the Imaging of Dementia and Aging (IDeA) laboratory.

His research focuses on using advanced structural and functional brain imaging to study normal aging, mild cognitive impairment and dementia and the role of genetics, diversity, cerebrovascular and Alzheimer's disease on these processes. He is a recipient of the J. Allyn Taylor International Prize in Medicine-Imaging of the Aging Brain in recognition of his work.

Professor Stéphane Lehéricy, MD,  Paris Brain Institute

Stéphane Lehéricy is Professor of Neuroradiology and head of the neuroradiology department at the Pitié-Salpêtrière Hospital (Paris) and Director of CENIR (Centre de neuro-imagerie de recherche) at the Paris Brain. His area of research is the structural and functional study of the normal and pathological human brain, including movement pathology and neurodegenerative dementia. He focuses on the functional anatomy of the ganglia at the base of the normal human brain and on movement disorders. He has contributed to the understanding of the functional anatomy of the basal ganglia using fMRI and the diffusion tensor.

 

END